The mean severe exacerbation rate was 0.33 per person per 26 weeks in the azithromycin group compared to 0.93 exacerbations per person in the placebo group ( incidence rate ratio ( 95 % CI ) : 0.37 ( 0.11,1.21 ) , p = 0.062 ) .